It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.29.24314577;](https://doi.org/10.1101/2024.09.29.24314577) this version posted September 30, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

Title page

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract : Nearly two decades ago, diabetes mellitus (DM) and cardiovascular disease (CVD) emerged as major global health threats, with research interest steadily increasing. Despite ongoing in-depth studies in the DM+CVD field, a systematic analysis of overall development trends and future hotspots remains lacking. This study employs bibliometric methods, utilizing CiteSpace and VOSviewer software to analyze and visualize 5,505 DM+CVD-related publications from 2005 to May 2024. The findings reveal a rapid growth trend in the field, with publications peaking at 751 in 2022, and the United States and China as major contributing countries. Keyword analysis identifies research hotspots including oxidative stress, insulin resistance, and heart failure. Highly cited literature analysis shows that the relationship between DM+CVD and obesity, disease mechanisms, treatment strategies, lifestyle interventions, and novel drugs are primary research themes. Analysis of highly cited literature from the past three years indicates that the application of SGLT2 inhibitors and GLP-1 receptor agonists, the association between metabolic abnormalities and DM+CVD, precise management of heart failure and cardiomyopathy, and in-depth epidemiological studies are current and future research priorities. This study not only reveals research hotspots and development trends in the DM+CVD field but also provides important references for optimizing research resource allocation and promoting multidisciplinary collaboration.

 Keywords: Diabetes Mellitus; Cardiovascular Diseases; Hotspots and Frontiers; Bibliometrics; 53 Research Trends.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.29.24314577;](https://doi.org/10.1101/2024.09.29.24314577) this version posted September 30, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

79 attendance, and premature mortality due to DM, collectively resulting in a productivity loss of 80 96.5 billion USD⁶.

81 Cardiovascular Diseases (CVD) are one of the primary causes of death among patients with 82 DM^{7,8}, while DM is also a major risk factor for CVD⁹. According to a report by the American 83 Heart Association (AHA)¹⁰, at least 68% of DM patients aged 65 or older die from some form of 84 CVD; in China, the proportion of T2DM patients who die from CVD is even higher, reaching 85 75%¹¹. The chronic hyperglycemic state in DM patients leads to a series of pathological changes, 86 such as endothelial cell dysfunction and vascular smooth muscle cell proliferation, which increase 87 the risk of cardiovascular disease^{7,12}. Furthermore, DM patients often present with a cluster 88 distribution of risk factors, including hypertension, obesity, and dyslipidemia², which further 89 increases cardiovascular risk. Epidemiological studies indicate that, compared to non-DM 90 populations, DM patients have a 5 to 15 percentage point higher risk of major cardiovascular 91 events such as coronary heart disease¹³.

 Despite the extensive research in the field of DM+CVD, systematic analyses of its research hotspots and frontiers remain relatively scarce. Given the profound impact of DM+CVD on 94 patient health and socioeconomic conditions¹⁴, a comprehensive understanding of the research dynamics in this field is of paramount importance. Therefore, this study aims to conduct a systematic analysis of the DM+CVD field using bibliometric methods, employing two literature visualization software tools: CiteSpace and VOSviewer. Compared to traditional systematic reviews, bibliometrics offers the advantage of summarizing research fields from a macro and comprehensive perspective, utilizing mathematical and statistical models for quantitative and 100 visual analysis of knowledge carriers^{15,16}. The CiteSpace and VOSviewer software tools selected

 for this study each have their unique features: CiteSpace is renowned for its robust temporal perspective functionality and rich analytical indicators, while VOSviewer is known for its intuitive 103 interface and high flexibility^{17,18}.By combining the strengths of these two software tools, we can scientifically identify active researchers, potential collaborators, popular topics, and future research frontiers in the field. Through this approach, we aim to provide a comprehensive reference of hotspots and frontiers in the DM+CVD field for relevant researchers, while also elucidating the research trajectory and evolutionary trends within this domain.

1**.Materials and Methods**

1.1.Data Source

The primary data source for this study was the Web of Science Core Collection (WOSCC) database, utilizing the SCI-Expanded index. To comprehensively cover DM+CVD-related research, we established the following search criteria: the search term combination was (TS=("diabetes" OR "diabetic") AND TS=("cardiovascular diseases" OR "cardiac diseases" OR "heart diseases")). Document types were restricted to "Article" and "Review Article", with all open access publications included. The language was limited to English, and the search timespan was set from January 1, 2005 to May 5, 2024.To explore the multifaceted impacts of DM+CVD in depth, we applied detailed restrictions to the citation topic Meso, encompassing but not limited to the following 34 fields (for a complete list, see Table S1): Diabetes, Phytochemicals, Lipids, Nutrition & Dietetics, and Cardiology - Circulation. Limiting these broad topic areas ensures that the research scope of DM+CVD is explored from multiple angles and levels. Through this multidisciplinary analytical approach, we can systematically evaluate research progress across various domains, from basic medicine to clinical practice, and from drug research to public health

 policy, thereby forming a comprehensive and in-depth analytical framework. Finally, using the aforementioned search method, 5505 publications were retrieved, including 3781 articles and 1724 reviews. The full records and references were imported into CiteSpace and VOSviewer software for quantitative analysis.

1.2.Analytical Methods

 This study utilized CiteSpace 6.3R1 and VOSviewer software for the visualization analysis of selected publications. In the data preprocessing phase, we imported bibliographic data into CiteSpace for duplicate screening, which yielded no duplicate entries. For CiteSpace parameter configuration, the time span was set from 2005 to 2024, with annual time slices. Term sources encompassed Title, Abstract, Author Keywords (DE), and Keywords Plus (ID) to comprehensively capture key information from the literature. We employed pathfinder and pruning sliced networks algorithms for network pruning to optimize visualization outcomes. The Selection Criteria was set to TOPN, utilizing the software's default threshold of 50, while maintaining other parameters at their default values. In VOSviewer, we flexibly adjusted thresholds for each node based on visualization requirements, with other parameters adhering to default settings.For analytical dimensions, we selected authors, publishing institutions, countries/regions, keywords, and references as primary analytical foci to comprehensively grasp collaboration patterns and knowledge structures within the field. In terms of visualization mapping, we generated collaboration network diagrams, co-occurrence network diagrams of cited literature, and co-citation network diagrams of cited literature using CiteSpace and VOSviewer to visually represent their characteristics and relationships. Additionally, Scimago Graphica was employed in conjunction with VOSviewer to provide a more intuitive display of collaboration

 networks and research impact across countries/regions.To elucidate core research themes and their evolution, we utilized CiteSpace's keyword clustering functionality to conduct cluster analysis on key concepts in the research field, identifying primary research themes and corresponding concept clusters. Subsequently, we generated a Timeline-based Theme River diagram to visualize the developmental trajectories and historical evolution of different clusters. Furthermore, we constructed keyword density maps using VOSviewer to identify research hotspots and reveal the field's overall knowledge structure.To explore research frontiers and emerging trends, we analyzed highly cited literature and their keywords from the past three years using CiteSpace. Through keyword analysis functions, particularly the Spotlight algorithm, we uncovered the strength of associations between keywords. Concurrently, by employing the Burst Detection algorithm for in-depth analysis of highly cited literature from the past three years, we successfully captured rapidly emerging research hotspots.Moreover, we utilized Excel for processing and organizing raw data, and R (version 4.3.1) with ggplot2 and forecast packages, along with Excel, to generate supplementary statistical charts and graphs.

2.Analysis of Bibliometric Characteristics

2.1Publication Trends and Impact Analysis

 From January 2005 to December 2023, the WOSCC indexed a total of 5404 articles in the field of DM+CVD, as illustrated in Figure 1. The number of publications related to DM+CVD research has demonstrated a consistent annual increase, with particularly significant increases observed during the period of 2019-2022. During this time, the annual publication volume increased substantially compared to the previous year, with an average growth rate of 21.85%. The peak in publication output was reached in 2022, with 751 articles published. Although the

 data for 2023 indicates a slight decline, considering the overall trend and historical data, this may be interpreted as a short-term fluctuation based on the overall trend. It is noteworthy that at the time of this study's completion, publications for 2024 were still being continuously indexed.Given the non-linear growth characteristics of historical publication numbers, this study employed polynomial regression (second-order) to forecast the publication volume for 2024. Based on the predicted publication volume, it is estimated that 2024 will see approximately 812 publications, 95% CI [679, 946]. Judging from both the publication volume and short-term forecast results, it is evident that the attention and activity in the DM+CVD field continue to increase, garnering widespread interest from scholars. FIG 1. Annual publication volume in DM+CVD (2005-2024).

 The graph shows the annual number of publications in the field of diabetes mellitus and cardiovascular disease comorbidity (DM+CVD) from 2005 to 2023, with a forecast for 2024. Black points represent actual publication counts, while the black line shows the trend. The red point for 2024 indicates the forecasted value (812) based on polynomial regression. Equation of 181 the regression line and statistical parameters $(R^2, A$ Adjusted R^2 , p-value) are shown in the top left. The 95% confidence interval for the 2024 forecast (679-946) is displayed in the top right. Note: 2023 data may be incomplete due to ongoing indexing.

 The WOS citation report function indicates that the retrieved publications have accumulated a total of 272,346 citations, with an average of 49.47 citations per article. The H-index, which reflects the impact and reputation of relevant research, stands at 212 for publications in the DM+CVD field, demonstrating the significant academic influence and the depth and durability of research outcomes in this domain.The WOS journal analysis report function reveals that all

 publications from 2005 to May 2024 originated from 118 journals. This study primarily analyzed the top 10 journals by publication volume, as shown in Table 1. Among these, PLoS ONE published the highest number of articles at 199, closely followed by the *International Journal of Molecular Sciences* with 159 publications. *Cardiovascular Diabetology*, *Nutrients*, and *Circulation* also maintained publication volumes exceeding 100 articles each. Notably, among the top 10 journals by publication volume, MDPI-affiliated journals account for over 30% of the publications, while BMC-affiliated journals follow closely, comprising 19% of the total.The Impact Factor (IF) is a crucial metric for assessing a journal's academic influence. Among the top 10 journals by publication volume, *Circulation* has the highest IF at 37.8, while *Frontiers in Cardiovascular Medicine* has the lowest at 3.6. The distribution of H-indices follows a similar pattern to IF, with *Circulation* having the highest H-index of 674 and *Frontiers in Cardiovascular Medicine* the lowest at 69.In summary, research in the DM+CVD field demonstrates a sustained growth trend and exerts a profound and significant influence in academia. The continued attention from high-quality journals and high citation rates reflect the importance and research value of this field.

2.2Collaboration Network Analysis

 From 2005 to 2024, research in the DM+CVD field involved contributions from 159 countries/regions, 7,137 institutions, and 34,707 authors. As shown in Figure 2, international collaboration in this field exhibits distinct geographical distribution patterns. Figure 2(A) displays the top 25 countries ranked by collaboration intensity, with European countries being particularly densely represented, indicating active research cooperation in this region. Regarding inter-country collaborations, the connecting lines between the United States and China, as well as between the

 United States and the United Kingdom, are particularly thick, reflecting close collaborative relationships among these countries.Figure 2(B) presents the top 10 countries/regions ranked by publication output. The United States leads with 1,257 publications, while China ranks second with 1,032 publications. Notably, there is a significant gap in publication numbers between the United Kingdom (ranked third) and subsequent countries compared to the United States and China.A comprehensive analysis of collaboration networks and publication data highlights the prominent positions of the United States and China in this research field, demonstrating their global academic influence and research capabilities.

219 FIG 2. Map of countries/regions network cooperation (A) and top 10 countries/regions(B) in DM+CVD.

(A) World map showing international collaboration networks. Lines represent collaborative links

between countries, with different colors indicating distinct collaboration clusters. (B) Bar chart of

the top 10 countries by publication count. The United States (1287 publications) and China (1032

publications) lead in research output, followed by the United Kingdom, Italy, and Japan.

 The institutional collaboration network is depicted in Figure 3. In Figure 3(A), node size represents each institution's publication output, while Figure 3(B) displays specific publication data. Harvard University tops the list with 226 publications, followed by Harvard Medical School (139) and University of London (134). Notably, 60% of the top 10 institutions by publication count are from the USA, highlighting the country's dominant position and substantial contributions in this research field. This phenomenon also reflects the research strength and innovative capacity of American academic institutions in this domain.

232 FIG.3 Institutional Cooperation Network (A) and top 10 Affiliations(B) in DM+CVD.

 (A) Visualization of institutional collaboration network. Nodes represent institutions, with size indicating publication volume. Colors denote different collaboration clusters. Lines represent collaborative links between institutions. (B) Bar chart showing top 10 institutions by publication count. Harvard University (USA) leads with 208 publications, followed by Harvard Medical 237 School (USA) with 139 publications.

 Figure 4 illustrates the author collaboration network and the top 10 authors by publication count.The intensity of the connecting lines in the network reflects the closeness of collaboration among authors. The top 10 authors typically have dense connections with other researchers, indicating their key roles in the collaborative network. It is noteworthy that some Chinese scholars, including Yang Ling, Chen Junshi, and Guo Yu, also show dense interconnections, reflecting the active engagement of Chinese research teams in this field.Among the top 25 ranked authors, 24% are Swedish, 20% are American, while among Asian countries, Japanese scholars comprise the highest proportion at 12%, followed by Chinese scholars at 8%. This distribution further accentuates the leading position of European and American countries in this field, while also signifying the increasingly significant roles of Asian countries, particularly Japan and China.

248 FIG.4 Author Cooperation Network (A) and top 10 Authors(B) in DM+CVD.

 (A) Visualization of author collaboration network. Nodes represent individual authors, with size indicating publication volume. Colors denote different collaboration clusters. Lines represent co-authorship links. (B) Bar chart showing top 10 authors by publication count.

 In conclusion, within the interdisciplinary field of DM+CVD research, the United States, China, and European countries demonstrate notably high contributions. The United States maintains a leading position in overall research output, while European countries exhibit a more

 densely interconnected collaboration network. Asian countries, particularly China and Japan, also showcase robust research capabilities. This diverse landscape of international collaboration not only promotes knowledge exchange and innovation but also lays a solid foundation for the global development of this field.

2.3 Keyword Analysis: Dynamics and Trends

 Through an analysis of keywords from 5,505 publications in the DM+CVD field, we systematically identified the research hotspots and developmental trends in this domain. VOSviewer data revealed a total of 8,250 keywords, with 16 keywords occurring more than 100 times. The keyword co-occurrence, cluster analysis, density distribution, and keyword bursts are illustrated in Figure 5.In the keyword co-occurrence network (Figure 5A), node size reflects keyword frequency. Larger nodes for terms such as "cardiovascular disease," "diabetes mellitus," and "obesity" align with the VOSviewer statistical data (Figures 5C, 5D) and correspond to our research focus. Other prominent keywords include "insulin resistance," "hypertension," "metabolic syndrome," and "inflammation," reflecting disease-related factors, risk factors, and pathophysiological processes associated with DM+CVD from various perspectives.Keywords like "gene expression" and "oxidative stress" indicate researchers' interest in the fundamental mechanisms of DM+CVD. Terms such as "blood pressure" and "heart failure" highlight research hotspots in clinical manifestations and complications. Descriptive terms like "association" and "impact" correspond to scholars' diverse research interests in different aspects of DM+CVD, reflecting to some extent the multidimensionality and complexity of research in this field.

 To better understand the underlying logic behind the keywords, we conducted a cluster analysis, with results shown in Figure 5B. The clustering indicators yielded a Q value of 0.4358

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.29.24314577;](https://doi.org/10.1101/2024.09.29.24314577) this version posted September 30, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

 latest trends in DM+CVD research, namely an in-depth exploration of disease mechanisms, reassessment of epidemiological characteristics, and a focus on specific complications such as heart failure and diabetic cardiomyopathy.Additionally, we observed that certain keywords, such as "mechanism," although present in research as early as 2007, did not show a significant burst trend until 2022. This lag phenomenon may indicate a shift in research focus from phenomenon description to mechanism exploration, reflecting an increase in knowledge accumulation and research depth within the field.Simultaneously, we noted that some earlier hotspots, such as CRP and acute myocardial infarction (18.18, 2005-2012), have concluded their burst periods. This may suggest that related research has matured or that research priorities have shifted. FIG 5. Keyword co-occurrence (A), clustering (B), density map (C), top 20 keywords (D) and Top 25keywords bursts(E) in the field of DM+CVD (2005-2024). (A) Keyword co-occurrence network. Node size indicates keyword frequency; colors represent different clusters.(B) Clusters of major research topics. Colored clusters show the evolution of research themes over time.(C) Density visualization of keyword co-occurrence. Red areas indicate high-frequency keywords and their relationships.(D) Bar chart of top 20 keywords by frequency. 'Cardiovascular disease' and 'diabetes mellitus' are the most frequent terms.(E) Top 25 keywords with the strongest citation bursts, showing emergence years and burst durations. The analysis of keywords and their evolutionary trends reveals the diversity and progression of research hotspots in the field. There has been a notable shift from the early focus on inflammatory markers and acute cardiovascular events to a more in-depth exploration of specific complications, such as diabetic cardiomyopathy and heart failure. The recently emerging keywords indicate that current research is concentrating on a deeper understanding of disease mechanisms and a

 reassessment of epidemiological characteristics. This progression demonstrates the continuous advancement of scientific knowledge in the DM+CVD field.

3.Analysis of Highly Cited Papers

 Building upon our earlier keyword analysis that revealed research hotspots and trends in the DM+CVD field, we now turn our attention to the analysis of highly cited papers. These publications encapsulate the most significant scientific achievements in a discipline and represent the developmental level of the field. Analyzing highly cited papers allows for a comprehensive understanding of the structural framework and overall characteristics of the discipline.Figure 6 presents a dual-map overlay of research journals in the DM+CVD field, broadly illustrating two primary citation pathways. Published articles primarily fall within the domains of medicine, clinical research, molecular biology, and immunology, while cited literature predominantly originates from journals in health, nursing, medicine, molecular biology, and genomics. This reflects the interdisciplinary nature of research in this field and the balance between basic research and clinical applications.VOSviewer data indicate that 5,505 articles encompass 269,272 citations. As shown in Figure 7, there are 10 main clusters, including: #0 coronary disease, #1 treatment outcome, #2 heart failure, #3 myocardial infarction, #4 diabetes mellitus, #5 asymmetric dimethylarginine, #6 resveratrol, #7 epidemiology, #8 insulin resistance, #9 protein kinases, and #10 myocardial biology. These clusters reveal the core issues and research hotspots in the field.Through statistical and visual analysis of highly cited papers, combined with the citation report function of WOSCC, we discussed novel findings and key literature driving the development of the discipline, encompassing 28 articles and 22 reviews.

FIG 6. Dual-map overlay of the journals on DM+CVD research (2005-2024).Left side represents

- citing journals, right side represents cited journals. Each colored cluster represents a distinct
- research field. Lines connect citing journals to cited journals, showing interdisciplinary knowledge
- flow. Thickness of lines indicates citation frequency.
- FIG 7. Co-citation network (A), top50 co-cited literature (B), and Timeline-based Theme River
- diagram (C) in DM+CVD(2005-2024).
- (A) Co-citation network of authors generated by CiteSpace. Node size represents citation
- frequency; colors indicate publication year (blue for older, red for more recent).
- (B) Co-citation network of literature generated by VOSviewer. Nodes represent publications; links
- indicate co-citation relationships. Different colors represent distinct clusters, each corresponding
- to a specific research theme or sub-field.
- (C) Landscape view of research topics from 2000 to 2023 created by CiteSpace. Each colored
- stream represents a major research theme, with labels indicating specific topics. The width of
- streams indicates the relative prominence of topics over time
- *3.1Review.*

 Reviews not only help researchers gain a comprehensive understanding of existing research findings and developmental trends but also facilitate knowledge accumulation and dissemination while identifying and addressing key issues through expert perspectives. To ensure research quality, authority, and impact, we selected 22 highly cited reviews published in top-tier journals such as The Lancet, Circulation Research, Circulation, Endocrine Reviews, European Heart Journal, and Cell Metabolism for analysis. These reviews have been categorized by research topic and ordered chronologically to distill the core information of their content.

Research on the Relationship Between Obesity and Disease In 2005, Daniels SR et

 al.¹⁹reviewed the pathophysiological mechanisms of obesity in children and adolescents, elucidating how obesity leads to the development of DM band CVD through insulin resistance, chronic inflammation, and metabolic syndrome. This study not only provided crucial insights into understanding the pathogenesis of CVD in DM patients but also proposed multi-level prevention strategies encompassing lifestyle, family, community, and policy interventions, laying a 370 theoretical foundation for subsequent research and policy formulation.In 2009, Daphne et al.²⁰ conducted a meta-analysis synthesizing data from 89 studies. Their findings demonstrated a significant correlation between overweight/obesity and the risk of various chronic non-communicable diseases, particularly T2DM and CVD. By integrating extensive epidemiological data, this study provided robust evidence for understanding the association between overweight/obesity and DM/CVD.Prasenjit and Sushil²¹, in 2015, systematically explained how obesity exacerbates inflammatory responses through oxidative stress, thereby increasing the risk of T2DM and CVD. This deepened the understanding of the molecular mechanisms underlying obesity-related metabolic disorders.

379 As research progressed, Piché et al.²² proposed in 2020 that the phenotypic heterogeneity of obesity has diverse health impacts, with visceral fat accumulation significantly increasing the risk of CVD and DM. Further studies indicated that while overall obesity increases risk, the accumulation of fat in specific regions has a more pronounced effect on metabolic and 383 cardiovascular health²³. In 2021, the AHA issued a statement²⁴ systematically summarizing the relationship between obesity and CVD. It explicitly identified obesity as an independent risk factor for CVD while emphasizing the close relationship between obesity and T2DM. Moreover, the statement highlighted key areas for future research, such as developing upstream interventions

for young, severely obese patients for primary prevention and better chronic disease management.

- For older populations at risk of heart failure, strategies should focus on weight maintenance and
- improving functional outcomes rather than weight loss alone.

 Public Health Strategies for Diet and Exercise. In 2010, Micha Renata et al.²⁵ evaluated the differential health impacts of red and processed meat consumption. Their study indicated a significant positive correlation between processed meat intake and the risk of coronary heart disease and DM, while unprocessed red meat showed no such significant association. Subsequent research corroborated these findings, such as a meta-analysis published in *BMC Public Health*²⁶ in 395 2019 and a study based on UK Biobank data²⁷ in 2022. This accumulating scientific evidence has 396 begun to influence global public health policies, with the World Health Organization²⁸, the 397 International Agency for Research on Cancer $(IARC)²⁹$, and the European Society of 398 Cardiology(ESC)³⁰ all emphasizing the importance of reducing processed meat consumption.Beyond studies on specific foods, broader lifestyle interventions have also made 400 significant progress. In 2015, Pedersen³¹ comprehensively reviewed the evidence for exercise as a treatment modality in 26 chronic diseases, highlighting the substantial effect of regular physical activity combined with dietary interventions in reducing DM and cardiovascular disease (CVD) risk. In 2016, Mozaffarian Dariush³² published a review in *Circulation*, integrating the latest dietary scientific evidence and emphasizing the importance of specific foods and overall dietary patterns (such as the Mediterranean diet) in preventing and managing chronic diseases.

 Meanwhile, polyphenol research has provided new perspectives on lifestyle interventions. A 2015 review³³ indicated that antioxidant phytochemicals like polyphenols can effectively scavenge 408 excess oxidants, reducing oxidative stress levels. In 2018, Nour et al.³⁴ further elucidated the

 immunomodulatory and anti-inflammatory mechanisms of polyphenols, including immune cell regulation, inhibition of pro-inflammatory factors, and inactivation of NF-kB. These mechanisms demonstrate the potential benefits of polyphenols in preventing and managing various chronic diseases, particularly in improving insulin sensitivity and vascular function. In 2020, Mehdi et al.³⁵ conducted an in-depth analysis of the relationship between oxidative stress and various metabolic diseases, proposing lifestyle adjustments (such as increasing antioxidant intake and maintaining regular exercise) to improve oxidative stress status and thereby reduce disease burden. This research further reinforced the importance of antioxidants like polyphenols in chronic disease prevention. However, despite encouraging results from polyphenol research, Hannah et al.'s review³⁶ pointed out that currently only a few specific polyphenol compounds have received official approval for health claims, highlighting the need for enhanced regulation and research in this area.

 Additionally, the impact of food processing on polyphenol bioavailability requires further investigation to optimize their application in daily diets.

 Theoretical Advances in the Mechanistic Research of DM+CVD. The pathophysiological mechanism research of DM+CVD involves complex interactions across multiple levels and disciplines. Through systematic analysis of highly cited literature, we have identified three main research directions: (1) Reassessmentof adipose tissue function, (2) In-depth study of cellular signaling pathways, and (3) Regulatory role of miRNAs in disease progressionThese studies reveal the complex pathophysiological processes of the disease from different perspectives, providing important clues for understanding disease mechanisms and developing new therapeutic strategies.

 The reassessment of adipose tissue function is an important breakthrough in DM+CVD 432 research. In 2008, Hajer et al. published a comprehensive review in the European Heart Journal³⁷, summarizing the significant advances in the scientific community's understanding of adipose tissue function at that time. This review emphasized that adipose tissue is not merely a simple fat storage site, but plays a key role in metabolic regulation and endocrine function.Adipose tissue directly participates in the pathophysiological processes of DM and CVD by secreting various hormones and cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and plasminogen activator inhibitor-1 (PAI-1). These findings provided new perspectives for subsequent research, prompting researchers to reconsider the associations between obesity, DM, and CVD

 Research on cellular signaling pathways has further deepened our understanding of disease 442 mechanisms. In 2010, Geraldes Pedro and King George L³⁸ reviewed the potential role of protein kinase C (PKC) isoforms in the treatment of DM complications, which garnered widespread attention in the research community³⁹. Although Ruboxistaurin, a PKC-β inhibitor, has shown promise in the treatment of diabetic retinopathy, further studies are needed to confirm its efficacy 446 and safety in cardiovascular protection⁴⁰.

447 Research on microRNAs (miRNAs) has provided new insights into disease mechanisms^{41,42}. In 2012, Creemers Esther E et al.⁴³ reviewed the progress in circulating miRNAs (miRNAs present in body fluids such as blood) research in CVD, highlighting their potential value as biomarkers. While the potential of circulating miRNAs as biomarkers has gained widespread attention, the fundamental challenges in their clinical application may be more profound. These 452 include large individual variations in circulating miRNA expression⁴⁴ standardization issues in

453 detection methods⁴⁵, consistency in sample collection and processing⁴⁶ and the complexity in 454 interpreting the origins and functions of circulating miRNAs⁴⁷. Currently, these challenges limit the reliability of circulating miRNAs as diagnostic tools.

 In terms of therapeutic theory research. Recent studies have not only deepened our understanding of existing treatments but also paved the way for personalized and precision medicine.Metformin, a cornerstone in DM treatment, has been a focus of research regarding its mechanism of action and clinical applications. A highly cited paper published in *Cell Metabolism* in 2014⁴⁸elaborated on its mechanism and potential cardiovascular benefits. Despite metformin's crucial role in DM treatment, its use may increase the risk of lactic acidosis in patients with renal 462 impairment and high-risk cardiovascular conditions⁴⁹, necessitating caution. These challenges, however, present opportunities for precision medicine, enabling more precise and safer individualized treatment strategies through the study of drug characteristics in different 465 populations and clinical contexts.In 2016, Wang et al.⁵⁰ comprehensively updated recent research findings in a review article in Circulation. They noted that current treatment strategies primarily focus on glycemic control, overlooking other important mechanisms by which DM exacerbates atherosclerosis and heart failure, such as chronic inflammation and endothelial dysfunction, which may vary in presentation and impact among patients. These findings highlight the necessity of 470 personalized treatment approaches⁵¹. In the same year, Kautzky-Willer et al.⁵² further emphasized the importance of individualized treatment by analyzing the multifaceted impact of gender differences in T2DM. This study provided crucial evidence for developing gender-specific treatment strategies, though more clinical trials are needed to validate their efficacy.Forrester et al.⁵³, in a 2018 *Circulation Research* paper, delved into the mechanisms of reactive oxygen

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.29.24314577;](https://doi.org/10.1101/2024.09.29.24314577) this version posted September 30, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

 85-94. The number of CVD cases increased from 271 million in 1990 to 523 million in 498 2019^{58,59}. Regarding mortality, the age-standardized death rate (per 100,000 population) for DM increased from 18.2 in 1990 to 19.6 in 2021. Although the age-standardized death rate for 500 cardiovascular and circulatory system diseases decreased by 22% between 1990 and 2013⁵⁵, considering global demographic changes, the number of CVD deaths continues to rise. As of 502 2021, CVD deaths still accounted for one-third of global deaths⁵⁹.

503 There is a strong link between DM and CVD. Studies show⁴⁷ that for every 10-year increase in DM duration, the risk-factor-adjusted CVD risk increases by 1.38-fold, and the mortality risk increases by 1.86-fold. Although the incidence of CVD events among adult DM patients has decreased by 50% since the beginning of the 21st century, the absolute risk of CVD remains twice 507 that of non-DM populations⁵³.DM+CVD imposes a significant disease burden on global public health, with notable regional disparities54,55,60 In economically developed countries such as the United States and Western European nations, despite declining mortality rates for DM and CVD, incidence continues to rise, primarily attributed to population aging and increasing obesity rates57,61. In contrast, low- and middle-income countries exhibit high rates of both incidence and mortality for DM and CVD, potentially due to lower education levels and awareness of prevention 513 and control, weaker treatment capabilities, and insufficient healthcare resources⁶²⁻⁶⁴.

 These studies collectively emphasize the persistent nature of DM and CVD as major global health threats. They provide crucial evidence for developing effective public health strategies to address current health challenges, particularly in areas such as resource allocation, implementation of preventive measures, and healthcare system reforms. Future research should further explore prevention and management strategies for these diseases, especially in resource-limited regions.

 Clinical research advancements in DM+CVD diagnosis and treatment. Among the highly cited publications, 11 articles are related to this topic, covering biomarker studies, inflammation, and pharmaceutical research.

522 Biomarker researchplays a crucial role in the diagnosis and management of DM and CVD⁶⁵, deepening our understanding of disease mechanisms and providing new directions for diagnostic, preventive, and therapeutic strategies. In 2007, Goralski et al.⁶⁶ identified Chemerin as a novel adipokine that promotes insulin resistance by influencing insulin signaling and glucose 526 metabolism, emerging as a new biomarker for DM⁶⁷. Moreover, Chemerin increases CVD risk by promoting vascular inflammation and endothelial dysfunction, making it significant in cardiovascular risk assessment⁶⁸.In 2017, Ellulu et al. provided a multidimensional perspective on DM+CVD biomarker research69, revealing the complex interactions between obesity, chronic inflammation, and oxidative stress in DM+CVD pathogenesis. They found a negative correlation between pro-inflammatory factors (TNF-α, IL-6) and adiponectin levels, while CRP levels strongly correlated with CVD risk. This finding not only linked metabolic disorders with vascular pathology but also provided a theoretical basis for multi-target therapeutic strategies.

 However, these highly cited studies also reveal several challenges in biomarker application. Firstly, single biomarkers often fail to fully reflect the complex pathophysiological characteristics 536 of DM and CVD⁶⁹ suggesting that future research may need to develop multi-marker combination models. Secondly, these studies emphasize the importance of individual differences, as factors 538 such as race, age, and gender may influence biomarker expression and significance⁷⁰, Overall, the rapid advancement in biomarker research has opened new opportunities for elucidating mechanisms, diagnosis, and treatment of DM+CVD. Nevertheless, to translate these research

 findings into clinical practice, more large-scale, multicenter prospective studies are needed to validate their clinical application value.

 Inflammation plays a crucial role in understanding the pathophysiological mechanisms of diseases. In 2018, Ferrucci and Fabbri⁷¹ scientifically elucidated the roles of monocytes, macrophages, T cells, B cells, cellular senescence, and senescence-associated secretory phenotype (SASP) in CVD pathogenesis. These factors contribute to CVD risk by promoting the release of inflammatory mediators and exacerbating inflammatory responses. Numerous studies have 548 corroborated this perspective⁷¹⁻⁷⁴. Regulating endothelial nitric oxide synthase (eNOS) activity and function is an effective approach to mitigate inflammatory responses. However, eNOS 550 "uncoupling" can transform it into a superoxide (O_2) -) generating enzyme, thereby aggravating inflammation and CVD progression. Förstermann⁷⁵ noted that increasing tetrahydrobiopterin (BH4) levels or inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity could correct eNOS dysfunction, thus restoring its protective effects.

 In the complex pathological network of DM+CVD, inflammatory response serves as a critical link, with implications far beyond mere cytokine release. DM patients, chronically exposed to hyperglycemia, not only experience low-grade inflammation but also undergo fundamental 557 alterations in immune balance and metabolic regulation⁷⁶. This systemic dysregulation accelerates atherosclerosis progression through multidimensional, multilayered mechanisms, creating a 559 self-perpetuating cycle^{77,78}.

 Furthermore, we need to reconsider the dual role of inflammation in DM+CVD. While excessive inflammation is undoubtedly harmful, moderate inflammatory responses are necessary 562 for tissue repair and metabolic homeostasis⁷⁹. Therefore, future therapeutic strategies should aim

not to completely eliminate inflammation, but rather to reestablish a healthy inflammatory balance,

necessitating more refined regulatory approaches and long-term intervention strategies.

 Pharmaceutical research. In recent years, DM and CVD-related drug research has shown trends towards diversification and precision. Analysis of highly cited literature reveals that hot topics in drug research focus on sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), statins, antiplatelet drugs, 569 renin-angiotensin-aldosterone system (RAAS) inhibitors, and β-blockers^{80–82}. These drugs not only target glycemic control but also reflect multi-target intervention strategies for cardiovascular protection. The emergence of SGLT2i and GLP-1 RA, in particular, has provided new treatment options for DM+CVD patients, potentially altering clinical practice patterns.However, despite 573 GLP-1 RA showing significant effects in DM treatment⁸³, its role in preventing cardiovascular events remains controversial. A large-scale randomized controlled trial (RCT) by Pfeffer et al.⁸⁰demonstrated that lixisenatide was non-inferior to placebo in terms of major cardiovascular endpoint incidence in T2DM patients with acute coronary syndrome, but failed to prove its superiority. This finding challenges our traditional understanding of incremental drug efficacy while highlighting the difficulty of evaluating single intervention effects in complex disease networks.

 Another important point is the role of antiplatelet therapy in primary prevention of DM+CVD 581 warrants further attention. Research by De Berardis et al.⁸⁴revealed gender differences in the effects of low-dose aspirin and its potential bleeding risks. This finding not only emphasizes the importance of individualized treatment but also reflects the need for a more comprehensive consideration of the balance between risks and benefits when evaluating preventive interventions.

 Comprehensive management strategies. Ten articles are related to this topic. The combined management of DM and CVD is a complex process aimed at comprehensively reducing cardiovascular risk and improving patients' long-term prognosis and quality of life86. This requires consideration of multiple factors, including glycemic control, blood pressure management, lipid regulation (such as lowering LDL-C levels), weight management, and control of other cardiovascular risk factors. Achieving these goals necessitates addressing three core aspects: patient self-education and self-management, lifestyle interventions, and risk assessment.

 Patient self-management and self-education have undergone significant evolution over the past two decades, progressing from basic disease awareness education to comprehensive multifactorial interventions, and now to technology-driven precision management. In 2007, the AHA and American Diabetes Association (ADA)⁸⁵, along with the ESC and European 596 Association for the Study of Diabetes (EASD)⁸⁶, proposed fundamental frameworks for patient self-management in their respective joint guidelines, emphasizing disease awareness, lifestyle interventions, and medication adherence education. This phase focused on enhancing patients' basic understanding of their conditions and encouraging proactive lifestyle changes.As medical knowledge deepened, the 2013 guidelines introduced a more comprehensive management concept⁸⁷. This update expanded beyond singular glycemic control to integrate blood pressure and lipid management, while also incorporating psychological health into the overall management strategy.

 From 2019 onwards88–90 guideline updates reflect characteristics of the digital age, ushering patient self-management into a new era. The introduction of smart devices and telemedicine has created unprecedented possibilities for real-time monitoring and precision management. For

 instance, the use of continuous glucose monitoring systems (CGM) and smart blood pressure monitors allows patients and healthcare teams to track key indicators more accurately. These technologies not only improve the precision and timeliness of data collection but also enable healthcare teams to respond more rapidly to patient needs, facilitating multidisciplinary collaboration and ongoing support.

 Lifestyle interventions are an indispensable component in the comprehensive management of 613 DM+CVD. Research by Danaei et al.⁹¹ corroborates the stance of major European and American guidelines, affirming that scientific lifestyle interventions, including dietary control, increased physical activity, and smoking cessation, not only help reduce CVD risk but also improve DM management outcomes. Weight management, as an integrated result of these interventions, emerges as a core objective in preventing and controlling both diseases.Mora et al.⁹²further elucidated the importance of appropriate weight management, demonstrating that higher levels of physical activity can significantly reduce cardiovascular event risk through mechanisms affecting blood pressure and inflammation, among others. Concurrently, diet plays a crucial role in 621 management strategies. Healthy dietary habits, particularly those rich in plant polyphenols⁹³, offer cardiovascular protection by improving vascular function, lowering blood pressure, and reducing LDL oxidation.

 While these studies provide evidence for the efficacy of lifestyle interventions, translating them into clinical practice remains challenging. Factors such as socioeconomic status, healthcare accessibility, and patient adherence often influence intervention outcomes⁹⁴. Therefore, future efforts should focus on tailoring scientific interventions to patients' social resources, sustainability, and individual characteristics. Additionally, exploring methods to enhance long-term adherence

through digital health technologies warrants active investigation.

 Risk assessment plays a crucial role in early disease prevention and individualized 631 management. The Framingham Heart Study⁹⁵ provided a multifactorial risk assessment model for evaluating overall and specific CVD risks in primary care. This multivariate risk assessment approach advanced cardiovascular disease prevention strategies and laid the foundation for subsequent risk assessment tool development. In recent years, risk assessment tools in the DM+CVD field have continually evolved, transitioning from traditional static models to more dynamic, personalized approaches. Updates to tools such as the QRISK3 cardiovascular risk 637 assessment⁹⁶, Finnish Diabetes Risk Score⁹⁷, and dynamic heart failure risk prediction models⁹⁸ showcase advantages in integrating more dynamic data sources, considering a broader range of risk factors, and utilizing advanced statistical and machine learning methods. These advancements enable clinicians to formulate more targeted prevention and treatment strategies. Regarding blood glucose and blood pressure monitoring, CGM and home blood pressure monitoring (HBPM) have become increasingly recommended methods. CGM technology provides real-time, continuous monitoring of blood glucose levels, offering DM patients valuable insights into glucose fluctuations⁹⁹. HBPM supplies authentic blood pressure data from patients' daily lives, avoiding interference from "white coat effect" and "masked hypertension". HBPM data contributes to more accurate assessment of antihypertensive treatment efficacy, facilitating timely medication adjustments. Long-term HBPM data can also reveal circadian blood pressure rhythm changes, providing clues for identifying abnormal blood pressure patterns.

 In conclusion, these studies indicate that management strategies for DM+CVD are evolving towards more integrated, precise, and personalized approaches. The development of

 technology-driven precision management models, individualized lifestyle intervention programs, and dynamic risk assessment tools presents increased possibilities for improving the efficacy of DM+CVD combined management. However, it is important to acknowledge that implementing these comprehensive management strategies still faces challenges in translating theory into practice, particularly when considering individual patient differences and socioeconomic factors. Future research should focus on enhancing the translational impact of new technologies, improving patient adherence, and developing more individualized and dynamic risk assessment models to achieve precision management of DM and CVD.

4.Research Hotspots and Development Trends

 We attempted to discuss the research hotspots and trends in the field of DM+CVD by analyzing highly co-cited literature and their keywords from the past three years (2021-2023). The Citespace keyword analysis and its Spotlight function results are shown in Figure 8A. The Spotlight function of Citespace helps researchers quickly identify keywords that are widely cited 664 and have significant impact on the current research field¹⁷. The results indicate that the main keywords are Cardiovascular disease, Risk, Oxidative stress, Inflammation, Obesity, Heart failure, Body mass index, Adipose tissue, Mortality, and Insulin resistance. This suggests that current research trends continue to revolve around these important and persistent hot topics.

 FIG 8. Visualization of Highly Cited Literature Keywords and Time line in DM+CVD (2021-2024)

 (A) Keyword co-occurrence network generated by CiteSpace. Node and font size represent the intensity and frequency of keyword occurrence. Node color indicates different time periods, with darker colors representing more recent times. Links between nodes, determined by the Spotlight

 algorithm, indicate high correlation between keywords. (B) Timeline view of major research topics. Each colored line represents a distinct research theme, with nodes on the lines indicating specific topics. The curvature and span of each line demonstrate the emergence and fading of different research themes over time.

 Among the keywords, those in smaller fonts reflect emerging research directions gaining gradual attention, such as metabolic flexibility¹⁰⁰, development of mitochondria-targeted 679 therapeutic strategies¹⁰¹, and the role of epigenetics in cardiovascular diseases¹⁰². This indicates that researchers have been exploring more refined and individualized disease mechanisms and treatment approaches in recent years.Through the Spotlight algorithm, we observed significant associations between several groups of keywords, such as obesity and adipose tissue, cardiovascular disease and heart failure, and oxidative stress and inflammation. These close associations reflect the evolution and deepening of research focus over the past three years, while also revealing researchers' in-depth exploration of internal connections within specific topics.Specifically, the link between obesity and adipose tissue indicates that research is delving into the complex relationship between obesity and adipose tissue function, particularly in terms of 688 metabolic disorders and cardiovascular risk¹⁰³. The association between cardiovascular disease 689 and heart failure suggests the increasing importance of heart failure in DM+CVD research¹⁰⁴, possibly related to population aging and improvements in chronic disease management. The close connection between oxidative stress and inflammation demonstrates researchers' growing 692 recognition of the interplay between these two processes in various pathological states¹⁰⁵.

 Clustering of keywords yielded six categories, as shown in Figure 8B: #0 Inflammation, #1 Diabetic cardiomyopathy, #2 Risk factors, #3 Coronary artery disease, #4 Type 2 diabetes, and #5

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.29.24314577;](https://doi.org/10.1101/2024.09.29.24314577) this version posted September 30, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

 the inclusion of liraglutide in treatment regimens for type 2 diabetes patients with high 718 cardiovascular risk.Also in 2016, Heerspink et a^{81} retrospectively examined the significant cardiovascular and renal protective effects of SGLT2 inhibitors in treating DM and discussed their clinical applications, suggesting that SGLT2 inhibitors should be prioritized when treating diabetic 721 patients with high cardiovascular disease risk.In 2022, Solomon et al¹⁰⁸conducted a randomized, double-blind, placebo-controlled trial, concluding that SGLT2 inhibitors significantly reduced the risk of worsening heart failure and cardiovascular death in patients with mildly reduced or preserved ejection fraction heart failure, while improving patient symptoms. The results of this study have significantly impacted clinical practice in using the SGLT2 inhibitor dapagliflozin to 726 treat this type of heart failure patient.

727 Traditional T2DM management primarily focused on glycemic control, often utilizing 728 insulin and sulfonylureas¹⁰⁹. Cardiovascular disease prevention and treatment relied on statins, 729 antihypertensives, and antiplatelet agents¹¹⁰. This segregated approach potentially led to several 730 issues: dispersed treatment goals, increased risk of drug interactions, high medication burden for 731 patients, potential side effects such as hypoglycemia and weight gain, lack of synergistic effects, 732 and difficulties in achieving personalized precision treatment^{109,111}.

 In contrast, SGLT2 inhibitors and GLP-1 receptor agonists offer multifaceted clinical benefits in T2DM treatment. Moreover, these agents simultaneously improve glycemic control and cardiovascular health, thereby enhancing overall treatment efficacy and long-term 736 prognosis^{106–108}. Based on their comprehensive therapeutic effects and favorable safety profiles, authoritative bodies such as the ADA and EASD have prioritized SGLT2 inhibitors and GLP-1 receptor agonists in their clinical guidelines for specific high-risk diabetic

33

 patients89,112.Consequently, the mechanisms of action of SGLT2 inhibitors and GLP-1 receptor agonists remain a key focus of current and future research, particularly their physiological effects related to sodium metabolism. This ongoing investigation aims to better understand and apply these agents in the integrated management of DM and CVD. Among the 10 articles, 2 discuss the association between lipids, obesity, and DM+CVD. The 2019 ESC/EAS⁸⁹ guidelines on dyslipidemia management detail how to reduce CVD risk through

 lipid modulation. The guidelines emphasize early lipid risk intervention and lifestyle changes to effectively lower cardiovascular risk. For obese and DM patients, they particularly stress comprehensive management strategies to improve metabolic status and cardiovascular health. In 748 2021, the AHA released a scientific statement²⁴ on obesity and cardiovascular disease, identifying obesity as a major risk factor for various cardiovascular diseases. It directly increases cardiovascular disease incidence by inducing metabolic abnormalities such as dyslipidemia, hypertension, and T2DM. The AHA emphasizes the importance of lifestyle interventions and weight loss for obesity prevention and treatment.

 These two authoritative statements have profoundly influenced academia, clinical practice, public health policy, and public health education, advancing the comprehensive management and prevention of obesity and DM+CVD.

 Although the relationships between obesity, DM, and CVD have been extensively studied, we believe current and future research trends will continue to focus on these areas. This ongoing 758 focus is driven by several factors: the rising global prevalence of obesity¹¹³, DM, and CVD^{59,64}; 759 the crucial role of lipid metabolism abnormalities in these diseases⁹⁰; the incompletely elucidated complex pathophysiological mechanisms; increasing demands for personalized medicine114,115; the

 emergence of novel therapeutic approaches; and the necessity for multidisciplinary comprehensive management¹¹⁶. Through multidisciplinary collaboration and personalized strategies, the aim is to comprehensively enhance the prevention and management of obesity, DM, lipid metabolism disorders, and CVD.

 In the highly cited literature, three articles focus on the management of heart failure and cardiomyopathy. The 2016 ESC guidelines for heart failure treatment emphasized the importance of cardiac rehabilitation and self-management education, establishing the foundation for recent heart failure management¹¹⁷ These guidelines established ACE inhibitors, β-blockers, and MRAs as standard treatment regimens, detailed the diagnostic steps for heart failure, including clinical assessment, imaging, and laboratory tests, and introduced BNP and NT-proBNP as diagnostic tools. Additionally, they described acute heart failure management strategies in detail.Building on 772 the 2016 guidelines, the 2021 ESC guidelines¹¹⁸ incorporated new drugs such as SGLT2 inhibitors and ARNIs, refined ejection fraction classification, strengthened the use of BNP and NT-proBNP, and further emphasized personalized treatment based on patient-specific factors, including age and comorbidities.In 2019, Murtaza et al. systematically reviewed the research progress on diabetic cardiomyopathy (DCM)¹¹⁹ exploring the roles of metabolic abnormalities, oxidative stress, and inflammatory responses in DCM pathogenesis. They highlighted the potential of novel drugs, gene therapy, stem cell therapy, and lifestyle interventions in future treatments. This comprehensive review significantly impacted the advancement of early diagnosis and effective treatment of DCM.

 Although coronary heart disease remains a primary research focus, its study is relatively 782 mature, with declining incidence and mortality rates in many countries and regions globally⁵⁹.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.29.24314577;](https://doi.org/10.1101/2024.09.29.24314577) this version posted September 30, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

 Epidemiological research has consistently played a crucial role in DM+CVD prevention and 806 control, and we believe it will remain a key research direction in the future¹²⁹. Epidemiological studies not only help us understand disease distribution, development trends, and influencing 808 factors but also provide scientific evidence for effective public health policy formulation¹³⁰. Ongoing epidemiological surveillance and research are essential for evaluating the effectiveness of interventions, predicting disease burden, optimizing resource allocation, and developing long-term prevention and control strategies. Considering that DM patients often face a higher risk of CVD, epidemiological research has unique advantages in revealing the association between these two types of diseases, exploring common risk factors, and assessing the effectiveness of 814 comprehensive prevention and control strategies¹³¹. In the future, with the development of big data and artificial intelligence technologies, epidemiological research is expected to play a greater role in disease warning, precision prevention, and personalized management, making more contributions to global DM and CVD prevention and control efforts.

 In summary, we find that the current and future development directions in DM+CVD are not about replacing traditional pathways, but rather about posing new challenges and updates to existing treatment and research methods.Traditional sulfonylureas and statins have shown some efficacy in treating DM or CVD individually, but face challenges when addressing DM combined with CVD or more complex situations. The impact of obesity and abnormal lipid metabolism in DM+CVD patients cannot be overlooked; while weight reduction and lipid metabolism regulation have demonstrated significant clinical benefits in improving prognosis for these patients, their mechanisms of action and optimal intervention strategies are not yet fully elucidated.Although coronary heart disease still dominates DM+CVD research, heart failure and cardiomyopathy are

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.29.24314577;](https://doi.org/10.1101/2024.09.29.24314577) this version posted September 30, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

- distribution pattern. While the United States and China dominate in publication volume, European
-
- countries, particularly Sweden, stand out in rankings of highly productive authors and institutions.

849 This distribution reflects the global nature of DM+CVD research while potentially indicating regional differences in research priorities.Subsequently, we focused on keywords and highly cited literature. After a comprehensive evaluation of the 5,505 publications from 2005-2024, we analyzed 50 highly cited papers in depth, including 22 reviews and 28 original research articles. Special attention was given to research developments in the past three years (2021-2023) to better understand future trends in the field.

 The review analysis reveals the evolution of the theoretical framework in DM+CVD research. Specifically, in studying obesity and disease relationships, the perspective has shifted from viewing obesity as a simple disease risk factor to recognizing its phenotypic heterogeneity and differential impact on DM and CVD, ultimately emphasizing multi-level prevention and intervention strategies across the life course. In lifestyle intervention and public health research, 860 the focus has progressed from examining the health effects of single food components to studying 861 the combined role of overall dietary patterns and regular exercise, and finally to integrating dietary interventions into broader public health policy frameworks.Mechanistic studies have demonstrated in-depth exploration at multiple biological levels, including reassessment of tissue function, deeper investigation of cellular signaling pathways, and new discoveries in molecular regulatory mechanisms. Treatment strategies have advanced from single-disease management models to comprehensive risk control and individualized precision therapy.

 Analysis of original research illustrates the development from theory to clinical practice. Epidemiological studies have quantified the global disease burden of DM+CVD, providing empirical evidence for evidence-based public health strategies. Clinical diagnosis and treatment research encompasses the identification of novel biomarkers, elucidation of inflammation's central

 role in disease pathophysiology, and efficacy validation of new drugs. Management strategy research reflects a transition from basic awareness education to technology-driven, multi-factorial,

and multi-disease comprehensive risk control.

 Finally, through analysis of highly cited literature from the past three years, we identified or predicted future research priorities in the field, including: novel drug intervention strategies, pathophysiological associations between metabolic abnormalities and DM+CVD, precision management of cardiovascular complications, and more extensive epidemiological research.

 In nearly two decades, despite significant advancements in this field, we have identified several persistent challenges. The long-term effects and precise mechanisms of novel drugs require further investigation. Clinical application of biomarkers faces issues of standardization and individualization. Achieving a precise balance in inflammation regulation remains a complex problem. Notably, effectively preventing and managing obesity at the population level to reduce 883 DM+CVD incidence continues to be a major challenge. In general, DM+CVD research is evolving from descriptive and observational studies towards mechanism-oriented and personalized approaches, with obesity consistently emerging as a key factor. Looking ahead, interdisciplinary collaboration and translational medical research will play crucial roles in driving breakthrough progress in the DM+CVD field, particularly in deciphering the complex relationships between obesity and DM+CVD. This not only holds promise for improving patient outcomes but may also provide insights for managing other obesity-related complex chronic diseases.

Acknowledgments

We thank the Science and Technology Department of Xinjiang Uygur Autonomous Region and

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

926 Complications study. *Diabetes Care*. 2007;30(8):2107-2112. doi:10.2337/dc06-1441

- 927 13. Thomas R. Einarson, Annabel Acs, Craig Ludwig, Ulrik H. Panton. Prevalence of 928 cardiovascular disease in type 2 diabetes: a systematic literature review of scientific 929 evidence from across the world in 2007-2017. *Cardiovasc Diabetol*. 2018;17(1):83. 930 doi:10.1186/s12933-018-0728-6
- 931 14. Hou Q, Li Y, Li S, Tian H. The global burden of diabetes mellitus. Chinese Journal of 932 Diabetes. 2016;24(1):92-96. doi:10.3969/j.issn.1006-6187.2016.01.023.
- 933 15. Cheng K, Guo Q, Yang W, Wang Y, Sun Z, Wu H. Mapping Knowledge Landscapes and 934 Emerging Trends of the Links Between Bone Metabolism and Diabetes Mellitus: A 935 Bibliometric Analysis From 2000 to 2021. *Front Public Health*. 2022;10. 936 doi:10.3389/fpubh.2022.918483
- 937 16. Lv J, Li Y, Shi S, et al. Frontier and Hotspot Evolution in Cardiorenal Syndrome: A 938 Bibliometric Analysis From 2003 to 2022. *Current Problems in Cardiology*. 939 2023;48(8):101238. doi:10.1016/j.cpcardiol.2022.101238
- 940 17. Chen C, Hu Z, Liu S, Tseng H. Emerging trends in regenerative medicine: a scientometric 941 analysis in CiteSpace. *Expert Opin Biol Ther*. 2012;12(5):593-608. 942 doi:10.1517/14712598.2012.674507
- 943 18. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric 944 mapping. *Scientometrics*. 2010;84(2):523-538. doi:10.1007/s11192-009-0146-3
- 945 19. S. R. Daniels, D. K. Arnett, R. H. Eckel, et al. Overweight in children and adolescents -946 Pathophysiology, consequences, prevention, and treatment. *Circulation*. 947 2005;111(15):1999-2012. doi:10.1161/01.CIR.0000161369.71722.10
- 948 20. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of 949 co-morbidities related to obesity and overweight: a systematic review and meta-analysis. 950 *BMC Public Health*. 2009;9:88. doi:10.1186/1471-2458-9-88
- 951 21. Manna P, Jain SK. Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated 952 Health Risks: Causes and Therapeutic Strategies. *Metab Syndr Relat Disord*. 953 2015;13(10):423-444. doi:10.1089/met.2015.0095
- 954 22. Piché ME, Tchernof A, Després JP. Obesity Phenotypes, Diabetes, and Cardiovascular 955 Diseases. *Circ Res*. 2020;126(11):1477-1500. doi:10.1161/CIRCRESAHA.120.316101
- 956 23. Després JP. Body fat distribution and risk of cardiovascular disease: an update. *Circulation*. 957 2012;126(10):1301-1313. doi:10.1161/CIRCULATIONAHA.111.067264
- 958 24. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific 959 Statement From the American Heart Association. *Circulation*. 2021;143(21):E984-E1010. 960 doi:10.1161/CIR.0000000000000973

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.09.29.24314577;](https://doi.org/10.1101/2024.09.29.24314577) this version posted September 30, 2024. The copyright holder for this

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

961 25. Micha R, Wallace SK, Mozaffarian D. Red and Processed Meat Consumption and Risk of 962 Incident Coronary Heart Disease, Stroke, and Diabetes Mellitus A Systematic Review and 963 Meta-Analysis. *Circulation*. 2010;121(21):2271-U52. 964 doi:10.1161/CIRCULATIONAHA.109.924977

965 26. Wang M, Ma H, Song Q, et al. Red meat consumption and all-cause and cardiovascular 966 mortality: results from the UK Biobank study. *Eur J Nutr*. 2022;61(5):2543-2553. 967 doi:10.1007/s00394-022-02807-0

968 27. Cui K, Liu Y, Zhu L, Mei X, Jin P, Luo Y. Association between intake of red and processed 969 meat and the risk of heart failure: a meta-analysis. *BMC Public Health*. 2019;19(1):354. 970 doi:10.1186/s12889-019-6653-0

- 971 28. World Health Organization. Global Action Plan for the Prevention and Control of 972 Noncommunicable Diseases 2013-2020. Geneva, Switzerland: World Health Organization; 973 2013
- 974 29. Wild CP, Weiderpass E, Stewart BW, eds. World Cancer Report: Cancer Research for Cancer 975 Prevention. Lyon, France: International Agency for Research on Cancer; 2020

976 30. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease 977 prevention in clinical practice. Eur Heart J. 2016;37(29):2315-2381. 978 doi:10.1093/eurheartj/ehw106

979 31. Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing exercise as therapy in 980 26 different chronic diseases. *Scand J Med Sci Sports*. 2015;25 Suppl 3:1-72. 981 doi:10.1111/sms.12581

982 32. Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and 983 Obesity A Comprehensive Review. *Circulation*. 2016;133(2):187-225. 984 doi:10.1161/CIRCULATIONAHA.115.018585

985 33. Zhang YJ, Gan RY, Li S, et al. Antioxidant Phytochemicals for the Prevention and Treatment 986 of Chronic Diseases. *Molecules*. 2015;20(12):21138-21156. 987 doi:10.3390/molecules201219753

988 34. Yahfoufi N, Alsadi N, Jambi M, Matar C. The Immunomodulatory and Anti-Inflammatory 989 Role of Polyphenols. *Nutrients*. 2018;10(11):1618. doi:10.3390/nu10111618

990 35. Sharifi-Rad M, Anil Kumar NV, Zucca P, et al. Lifestyle, Oxidative Stress, and Antioxidants: 991 Back and Forth in the Pathophysiology of Chronic Diseases. *Front Physiol*. 2020;11:694. 992 doi:10.3389/fphys.2020.00694

993 36. Cory H, Passarelli S, Szeto J, Tamez M, Mattei J. The Role of Polyphenols in Human Health 994 and Food Systems: A Mini-Review. *Front Nutr*. 2018;5:87. doi:10.3389/fnut.2018.00087

995 37. Hajer GR, van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes,

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

996 and vascular diseases. *Eur Heart J*. 2008;29(24):2959-2971. doi:10.1093/eurheartj/ehn387

- 997 38. Geraldes P, King GL. Activation of Protein Kinase C Isoforms and Its Impact on Diabetic 998 Complications. *CircRes*. 2010;106(8):1319-1331. doi:10.1161/CIRCRESAHA.110.217117
- 999 39. Bence Hegyi, Johanna M. Borst, Logan R. J. Bailey, et al. Hyperglycemia regulates cardiac K+ 1000 channels via O-GlcNAc-CaMKII and NOX2-ROS-PKC pathways. *Basic Res Cardiol*. 1001 2020;115(6):71. doi:10.1007/s00395-020-00834-8
- 1002 40. He Z, King GL. Can Protein Kinase C β–Selective Inhibitor, Ruboxistaurin, Stop Vascular 1003 Complications in Diabetic Patients? *Diabetes Care*. 2005;28(11):2803-2805. 1004 doi:10.2337/diacare.28.11.2803
- 1005 41. Mardis ER. DNA sequencing technologies: 2006–2016. *Nat Protoc*. 2017;12(2):213-218. 1006 doi:10.1038/nprot.2016.182
- 1007 42. Shendure J, Ji H. Next-generation DNA sequencing. *Nat Biotechnol*. 2008;26(10):1135-1145. 1008 doi:10.1038/nbt1486
- 1009 43. Creemers EE, Tijsen AJ, Pinto YM. Circulating MicroRNAs Novel Biomarkers and 1010 Extracellular Communicators in Cardiovascular Disease? *CircRes*. 2012;110(3):483-495. 1011 doi:10.1161/CIRCRESAHA.111.247452
- 1012 44. Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenges in using circulating 1013 miRNAs as cancer biomarkers. *Biomed Res Int*. 2015;2015:731479. 1014 doi:10.1155/2015/731479
- 1015 45. Felekkis K, Papaneophytou C. Challenges in Using Circulating Micro-RNAs as Biomarkers for 1016 Cardiovascular Diseases. *Int J Mol Sci*. 2020;21(2):561. doi:10.3390/ijms21020561
- 1017 46. Tijsen AJ, Pinto YM, Creemers EE. Circulating microRNAs as diagnostic biomarkers for 1018 cardiovascular diseases. *Am J Physiol Heart Circ Physiol*. 2012;303(9):H1085-1095. 1019 doi:10.1152/ajpheart.00191.2012
- 1020 47. Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Profiling of circulating microRNAs: from 1021 single biomarkers to re-wired networks. *Cardiovascular Research*. 2012;93(4):555-562. 1022 doi:10.1093/cvr/cvr266
- 1023 48. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: From Mechanisms of Action 1024 to Therapies. *Cell Metab*. 2014;20(6):953-966. doi:10.1016/j.cmet.2014.09.018
- 1025 49. Kwon S, Kim YC, Park JY, et al. The Long-term Effects of Metformin on Patients With Type 2 1026 Diabetic Kidney Disease. *Diabetes Care*. 2020;43(5):948-955. doi:10.2337/dc19-0936
- 1027 50. Wang CCL, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in 1028 Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 1029 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. *Circulation*.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

1030 2016;133(24):2459-2502. doi:10.1161/CIRCULATIONAHA.116.022194

- 1031 51. Ashley EA. The Precision Medicine Initiative A New National Effort. *JAMA-J Am Med Assoc*. 1032 2015;313(21):2119-2120. doi:10.1001/jama.2015.3595
- 1033 52. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology 1034 and Complications of Type 2 Diabetes Mellitus. *Endocr Rev*. 2016;37(3):278-316. 1035 doi:10.1210/er.2015-1137
- 1036 53. Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK. Reactive Oxygen Species in 1037 Metabolic and Inflammatory Signaling. *CircRes*. 2018;122(6):877-+. 1038 doi:10.1161/CIRCRESAHA.117.311401
- 1039 54. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980– 1040 2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 1041 2017;390(10100):1151-1210. doi:10.1016/S0140-6736(17)32152-9
- 1042 55. Global, regional, and national incidence, prevalence, and years lived with disability for 301 1043 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis 1044 for the Global Burden of Disease Study 2013. *Lancet*. 2015;386(9995):743-800. 1045 doi:10.1016/S0140-6736(15)60692-4
- 1046 56. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1047 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global 1048 Burden of Disease Study 2021. *Lancet*. 2023;402(10397):203-234. 1049 doi:10.1016/S0140-6736(23)01301-6
- 1050 57. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: a 1051 report from the American Heart Association. *Circulation*. 2013;127(1):e6-e245. 1052 doi:10.1161/CIR.0b013e31828124ad
- 1053 58. GBD_2021_CoD_infographic_6G_2024.04.03_ZH.pdf. Accessed May 30, 2024. 1054 https://www.healthdata.org/sites/default/files/2024-04/GBD_2021_CoD_infographic_6G_ 1055 2024.04.03_ZH.pdf
- 1056 59. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk 1057 Factors, 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol*. 1058 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010
- 1059 60. GBD 2013 DALYs and HALE Collaborators, Murray CJL, Barber RM, et al. Global, regional, 1060 and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy 1061 life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological 1062 transition. *Lancet*. 2015;386(10009):2145-2191. doi:10.1016/S0140-6736(15)61340-X
- 1063 61. Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: 1064 A Report From the American Heart Association. *Circulation*. 2019;139(10):e56-e528. 1065 doi:10.1161/CIR.0000000000000659

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

1066 62. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a 1067 pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet*. 1068 2016;387(10027):1513-1530. doi:10.1016/S0140-6736(16)00618-8

- 1069 63. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of 1070 hypertension in rural and urban communities in high-, middle-, and low-income countries. 1071 *JAMA*. 2013;310(9):959-968. doi:10.1001/jama.2013.184182
- 1072 64. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 1073 2019 and projections for 2030 and 2045: Results from the International Diabetes 1074 Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract*. 2019;157:107843. 1075 doi:10.1016/j.diabres.2019.107843
- 1076 65. Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in 1077 cardiovascular diseases: landscape and limitations. *Cardiovasc Diabetol*. 2022;21(1):68. 1078 doi:10.1186/s12933-022-01511-x
- 1079 66. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates 1080 adipogenesis and adipocyte metabolism. *J Biol Chem*. 2007;282(38):28175-28188. 1081 doi:10.1074/jbc.M700793200
- 1082 67. Zhao L, Zhou J, Abbasi F, et al. Chemerin in Participants with or without Insulin Resistance 1083 and Diabetes. *Biomedicines*. 2024;12(4):924. doi:10.3390/biomedicines12040924

1084 68. Pirsaraei VA, Khodabandehloo H, Mousavi MA, Zhiani M, Nazari S, Fathi M. Association of 1085 RARRES2 rs17173608 gene polymorphism and serum Chemerin with acute myocardial 1086 infarction and its risk factors: A case-control study in an Iranian population. *Gene*. 1087 2024;900:148020. doi:10.1016/j.gene.2023.148020

- 1088 69. Dhingra R, Vasan RS. Biomarkers in Cardiovascular Disease. *Trends Cardiovasc Med*. 1089 2017;27(2):123-133. doi:10.1016/j.tcm.2016.07.005
- 1090 70. Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting 1091 Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged 1092 Explanation and Elaboration. *J Natl Cancer Inst*. 2018;110(8):803-811. 1093 doi:10.1093/jnci/djy088
- 1094 71. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, 1095 and frailty. *Nat Rev Cardiol*. 2018;15(9):505-522. doi:10.1038/s41569-018-0064-2
- 1096 72. Yu HT, Park S, Shin EC, Lee WW. T cell senescence and cardiovascular diseases. *Clin Exp* 1097 *Med*. 2016;16(3):257-263. doi:10.1007/s10238-015-0376-z
- 1098 73. Chen HJ, Tas SW, de Winther MPJ. Type-I interferons in atherosclerosis. *J Exp Med*. 1099 2020;217(1):e20190459. doi:10.1084/jem.20190459
- 1100 74. Serino A, Salazar G. Protective Role of Polyphenols against Vascular Inflammation, Aging

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

1101 and Cardiovascular Disease. *Nutrients*. 2018;11(1):53. doi:10.3390/nu11010053

- 1102 75. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from 1103 marvel to menace. *Circulation*. 2006;113(13):1708-1714. 1104 doi:10.1161/CIRCULATIONAHA.105.602532
- 1105 76. Tsalamandris S, Antonopoulos AS, Oikonomou E, et al. The Role of Inflammation in 1106 Diabetes: Current Concepts and Future Perspectives. *Eur Cardiol*. 2019;14(1):50-59. 1107 doi:10.15420/ecr.2018.33.1
- 1108 77. Hattar L, Mumtaz T, El Mouhayyar C, Matevossian A, Johnstone M. The Effects and 1109 Treatment of Inflammation on Diabetes Mellitus and Cardiovascular Disease. In: Johnstone 1110 M, Veves A, eds. *Diabetes and Cardiovascular Disease*. Springer International Publishing; 1111 2023:307-329. doi:10.1007/978-3-031-13177-6_10
- 1112 78. Henein MY, Vancheri S, Longo G, Vancheri F. The Role of Inflammation in Cardiovascular 1113 Disease. *Int J Mol Sci*. 2022;23(21):12906. doi:10.3390/ijms232112906
- 1114 79. Inflammation and cardiovascular disease: From mechanisms to therapeutics. *American* 1115 *Journal of Preventive Cardiology*. 2020;4:100130. doi:10.1016/j.ajpc.2020.100130
- 1116 80. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute 1117 Coronary Syndrome. *N Engl J Med*. 2015;373(23):2247-2257. doi:10.1056/NEJMoa1509225
- 1118 81. Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium Glucose 1119 Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and 1120 Kidney Effects, Potential Mechanisms, and Clinical Applications. *Circulation*. 1121 2016;134(10):752-772. doi:10.1161/CIRCULATIONAHA.116.021887
- 1122 82. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The 1123 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major 1124 outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme 1125 inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering 1126 Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002;288(23):2981-2997. 1127 doi:10.1001/jama.288.23.2981
- 1128 83. Trombara F, Cosentino N, Bonomi A, et al. Impact of chronic GLP-1 RA and SGLT-2I therapy 1129 on in-hospital outcome of diabetic patients with acute myocardial infarction. *Cardiovasc* 1130 *Diabetol*. 2023;22(1):26. doi:10.1186/s12933-023-01758-y
- 1131 84. De Berardis G, Sacco M, Strippoli GFM, et al. Aspirin for primary prevention of 1132 cardiovascular events in people with diabetes: meta-analysis of randomised controlled 1133 trials. *BMJ*. 2009;339:b4531. doi:10.1136/bmj.b4531
- 1134 85. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in 1135 people with diabetes mellitus - A scientific statement from the American Heart Association 1136 and the American Diabetes Association. *Diabetes Care*. 2007;30(1):162-172.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

1137 doi:10.2337/dc07-9917

- 1138 86. Authors/Task Force Members, Ryden L, Standl E, et al. Guidelines on diabetes, 1139 pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes 1140 and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the 1141 European Association for the Study of Diabetes (EASD). *European Heart Journal*. 1142 2006;28(1):88-136. doi:10.1093/eurheartj/ehl260
- 1143 87. Authors/Task Force Members, Rydén L, Grant PJ, et al. ESC Guidelines on diabetes, 1144 pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the 1145 Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society 1146 of Cardiology (ESC) and developed in collaboration with the European Association for the 1147 Study of Diabetes (EASD). *Eur Heart J*. 2013;34(39):3035-3087. 1148 doi:10.1093/eurheartj/eht108
- 1149 88. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and 1150 cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 1151 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486
- 1152 89. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of 1153 dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 1154 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455
- 1155 90. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart Disease and Stroke Statistics: A Report 1156 of US and Global Data From the American Heart Association. *Circulation*. 1157 2024;149(8):e347-e913. doi:10.1161/CIR.0000000000001209
- 1158 91. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United 1159 States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. *PLoS* 1160 *Med*. 2009;6(4):e1000058. doi:10.1371/journal.pmed.1000058
- 1161 92. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of 1162 cardiovascular events: potential mediating mechanisms. *Circulation*. 1163 2007;116(19):2110-2118. doi:10.1161/CIRCULATIONAHA.107.729939
- 1164 93. Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. 1165 *Oxid Med Cell Longev*. 2009;2(5):270-278. doi:10.4161/oxim.2.5.9498
- 1166 94. Aziz Z, Absetz P, Oldroyd J, Pronk NP, Oldenburg B. A systematic review of real-world 1167 diabetes prevention programs: learnings from the last 15 years. *Implementation Sci*. 1168 2015;10(1):1-17. doi:10.1186/s13012-015-0354-6
- 1169 95. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in 1170 primary care: the Framingham Heart Study. *Circulation*. 2008;117(6):743-753. 1171 doi:10.1161/CIRCULATIONAHA.107.699579
- 1172 96. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

1173 prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort 1174 study. *BMJ*. 2017;357:j2099. doi:10.1136/bmj.j2099

- 1175 97. Peng Y, Wang P, Gong J, et al. Association between the Finnish Diabetes Risk Score and 1176 cancer in middle-aged and older adults: Involvement of inflammation. *Metabolism*. 1177 2023;144:155586. doi:10.1016/j.metabol.2023.155586
- 1178 98. Jiang W, Siddiqui S, Barnes S, et al. Readmission Risk Trajectories for Patients With Heart 1179 Failure Using a Dynamic Prediction Approach: Retrospective Study. *JMIR Med Inform*. 1180 2019;7(4):e14756. doi:10.2196/14756
- 1181 99. Michael Yapanis, Steven James, Maria E Craig, David O'Neal, Elif I Ekinci. Complications of 1182 Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose 1183 Monitoring. *J Clin Endocrinol Metab*. 2022;107(6):e2221-e2236. 1184 doi:10.1210/clinem/dgac034
- 1185 100. Gershuni VM, Yan SL, Medici V. Nutritional Ketosis for Weight Management and Reversal 1186 of Metabolic Syndrome. *Curr Nutr Rep*. 2018;7(3):97-106. doi:10.1007/s13668-018-0235-0
- 1187 101. Ajoolabady A, Chiong M, Lavandero S, Klionsky DJ, Ren J. Mitophagy in cardiovascular 1188 diseases: molecular mechanisms, pathogenesis, and treatment. *Trends Mol Med*. 1189 2022;28(10):836-849. doi:10.1016/j.molmed.2022.06.007
- 1190 102. Shi Y, Zhang H, Huang S, et al. Epigenetic regulation in cardiovascular disease: mechanisms 1191 and advances in clinical trials. *Signal Transduct Target Ther*. 2022;7(1):200. 1192 doi:10.1038/s41392-022-01055-2
- 1193 103. González N, Moreno-Villegas Z, González-Bris A, Egido J, Lorenzo Ó. Regulation of visceral 1194 and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity 1195 and diabetes. *Cardiovascular Diabetology*. 2017;16(1):44. doi:10.1186/s12933-017-0528-4
- 1196 104. Crea F. Heart failure and ischaemic heart disease: new challenges and opportunities. *Eur* 1197 *Heart J*. 2024;45(30):2681-2685. doi:10.1093/eurheartj/ehae497
- 1198 105. Balan AI, Halațiu VB, Scridon A. Oxidative Stress, Inflammation, and Mitochondrial 1199 Dysfunction: A Link between Obesity and Atrial Fibrillation. *Antioxidants (Basel)*. 1200 2024;13(1):117. doi:10.3390/antiox13010117
- 1201 106. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and 1202 Mortality in Type 2 Diabetes. *N Engl J Med*. 2015;373(22):2117-2128. 1203 doi:10.1056/NEJMoa1504720
- 1204 107. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in 1205 Type 2 Diabetes. *N Engl J Med*. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827
- 1206 108. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly 1207 Reduced or Preserved Ejection Fraction. *N Engl J Med*. 2022;387(12):1089-1098.

49

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.29.24314577;](https://doi.org/10.1101/2024.09.29.24314577) this version posted September 30, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grant

1208 doi:10.1056/NEJMoa2206286

1209 109. Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes 1210 mellitus: progress toward personalized management. *Cardiovasc Diabetol*. 2022;21(1):74. 1211 doi:10.1186/s12933-022-01516-6

- 1212 110. Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering 1213 medications on cardiovascular outcomes in secondary prevention: a meta-analysis of 1214 randomized trials. *Eur Heart J*. 2018;39(14):1172-1180. doi:10.1093/eurheartj/ehx566
- 1215 111. Bashier A, Bin Hussain A, Abdelgadir E, Alawadi F, Sabbour H, Chilton R. Consensus 1216 recommendations for management of patients with type 2 diabetes mellitus and 1217 cardiovascular diseases. *Diabetol Metab Syndr*. 2019;11:80. 1218 doi:10.1186/s13098-019-0476-0
- 1219 112. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 1220 2022. A Consensus Report by the American Diabetes Association (ADA) and the European 1221 Association for the Study of Diabetes (EASD). *Diabetes Care*. 2022;45(11):2753-2786. 1222 doi:10.2337/dci22-0034
- 1223 113. Lahey R, Khan SS. Trends in Obesity and Risk of Cardiovascular Disease. *Curr Epidemiol Rep*. 1224 2018;5(3):243-251. doi:10.1007/s40471-018-0160-1
- 1225 114. Margaret Whillier, Jane Musial, Helen L. MacLaughlin. Evaluation of patient experience 1226 post structured education for diabetes self management (Dose Adjustment For Normal 1227 Eating-OzDAFNE). *Diabetes Research and Clinical Practice*. 2021;181. 1228 doi:10.1016/j.diabres.2021.109065
- 1229 115. Heejin Jin, Ye An Kim, Young Lee, et al. Identification of genetic variants associated with 1230 diabetic kidney disease in multiple Korean cohorts via a genome-wide association study 1231 mega-analysis. *BMC Medicine*. 2023;21(1):16. doi:10.1186/s12916-022-02723-4
- 1232 116. Foster D, Sanchez-Collins S, Cheskin LJ. Multidisciplinary Team-Based Obesity Treatment in 1233 Patients With Diabetes: Current Practices and the State of the Science. *Diabetes Spectr*. 1234 2017;30(4):244-249. doi:10.2337/ds17-0045
- 1235 117. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and 1236 treatment of acute and chronic heart failure: The Task Force for the diagnosis and 1237 treatment of acute and chronic heart failure of the European Society of Cardiology 1238 (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the 1239 ESC. *Eur Heart J*. 2016;37(27):2129-2200. doi:10.1093/eurheartj/ehw128
- 1240 118. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and 1241 treatment of acute and chronic heart failure. *Eur Heart J*. 2021;42(36):3599-3726. 1242 doi:10.1093/eurheartj/ehab368
- 1243 119. Murtaza G, Virk HUH, Khalid M, et al. Diabetic cardiomyopathy A comprehensive updated

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.09.29.24314577;](https://doi.org/10.1101/2024.09.29.24314577) this version posted September 30, 2024. The copyright holder for this

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

- 1245 120. Dunlay SM, Roger VL. Understanding the Epidemic of Heart Failure: Past, Present, and 1246 Future. *Curr Heart Fail Rep*. 2014;11(4):404-415. doi:10.1007/s11897-014-0220-x
- 1247 121. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin 1248 in Heart Failure. *N Engl J Med*. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190
- 1249 122. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes 1250 with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and 1251 meta-analysis of randomised trials. *Lancet Diabetes Endocrinol*. 2021;9(10):653-662. 1252 doi:10.1016/S2213-8587(21)00203-5
- 1253 123. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. *J* 1254 *Am Coll Cardiol*. 2012;59(24):2145-2153. doi:10.1016/j.jacc.2011.10.910
- 1255 124. Tomov ML, Gil CJ, Cetnar A, et al. Engineering Functional Cardiac Tissues for Regenerative 1256 Medicine Applications. *Curr Cardiol Rep*. 2019;21(9):105. doi:10.1007/s11886-019-1178-9
- 1257 125. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. *Card Fail Rev*. 1258 2017;3(1):7-11. doi:10.15420/cfr.2016:25:2
- 1259 126. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the 1260 United States: a policy statement from the American Heart Association. Circ Heart Fail. 1261 2013;6(3):606-619. doi:10.1161/HHF.0b013e318291329a
- 1262 127. Boehmer TK. Association Between COVID-19 and Myocarditis Using Hospital-Based 1263 Administrative Data — United States, March 2020–January 2021. *MMWR Morb Mortal* 1264 *Wkly Rep*. 2021;70. doi:10.15585/mmwr.mm7035e5
- 1265 128. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level 1266 diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract*. 1267 2022;183:109119. doi:10.1016/j.diabres.2021.109119
- 1268 129. Zhou B, Bentham J, Cesare MD, et al. Worldwide trends in blood pressure from 1975 to 1269 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million 1270 participants. *The Lancet*. 2017;389(10064):37-55. doi:10.1016/S0140-6736(16)31919-5
- 1271 130. Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality 1272 for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis 1273 for the Global Burden of Disease Study 2017. *The Lancet*. 2018;392(10159):1736-1788. 1274 doi:10.1016/S0140-6736(18)32203-7
- 1275 131. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting 1276 glucose, and risk of cause-specific death. *N Engl J Med*. 2011;364(9):829-841. 1277 doi:10.1056/NEJMoa1008862

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

1281 **Tables**

TABLE 1. TOP 10 jorunals with publication volume from 2005 to May 2024

N _O	Publication Titles	Counts	Percentage	H-index	IF	Publishers
			$($ %)		(2022)	
1	Plos One	199	3.615	435	3.7	Public Library Science
	International					
$\overline{2}$	Journal Of	159	2.888	269	5.6	MDPI
	Molecular					
	Sciences					
3	Cardiovascular	133	2.416	108	9.3	BMC
	Diabetology					
4	Nutrients	132	2.398	209	5.9	MDPI
5	Circulation	128	2.325	674	37.8	Lippincott Williams &
						Wilkins
6	Scientific Reports	85	1.544	315	4.6	Nature Portfolio
$\overline{7}$	Bmc Public Health	83	1.508	197	4.5	BMC
	Frontiers In					
8	Cardiovascular	75	1.362	69	3.6	Frontiers Media SA
	Medicine					
9	Frontiers In	75	1.362	120	5.2	
	Endocrinology					Frontiers Media SA
10	Molecules	75	1.362	227	4.6	MDPI

- 1282
- 1283

1284

1285

1286

1287

1288

1289

1290

1291 1292

1293

1294

1295

1296

1297

1298

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

TABLE 2.Top 25 authors in the filed of CVD in Diabetes from 2005 to 2024

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

[Heart Failure Association \(HFA\) of the ESC](http://dx.doi.org/10.1093/eurheartj/ehw128)

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Supplementary Table

 Table S1.Thematic Areas for Meso-level Citation Analysis

Publication Count and 2024 Forecast (Polynomial Regression)

A VOSviewer

B

Top 25 Keywords with the Strongest Citation Bursts

Ε

